Calidi Biotherapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CLDI NYSE American 2834 www.calidibio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories - Oct 27th, 2026 6:00 am
Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026 - Oct 19th, 2026 6:00 am
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency - Sep 25th, 2026 3:00 pm
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering - Sep 17th, 2026 7:10 am
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Sep 8th, 2026 6:00 am
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Aug 13th, 2026 2:30 pm
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference - Jul 27th, 2026 6:00 am
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers - Jul 21st, 2026 6:00 am
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 - Jul 20th, 2026 2:30 pm
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - Jul 8th, 2026 2:05 pm
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit - Jun 24th, 2026 6:00 am
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors - Jun 23rd, 2026 6:00 am
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study - Jun 16th, 2026 6:00 am
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9 - Jun 5th, 2026 10:00 am
Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting - May 26th, 2026 6:00 am
Calidi Biotherapeutics Provides Required NYSE American Disclosure - May 22nd, 2026 4:00 pm
Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston - May 13th, 2026 6:00 am
Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI - Apr 29th, 2026 6:00 am